Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Combinations in Stage III NSCLC (COAST)
NCT03822351Phase 2Completed
- Sponsor
- MedImmune
- Start
- Dec 2018
- Primary completion
- Jul 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of oleclumab and monalizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by MedImmune. Primary endpoint: Objective Response Rate at 16 weeks. Started Dec 2018; status: completed.
02
Drugs
oleclumabmonalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03822351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822351.